Over the course of the past month, the Northwest Biotherapeutics Inc (OTCMKTS:NWBO) stock has been in the middle of a strong run and has managed to record gains to the tune of as much as 28% during the period.
On Friday, NWBO stock fell 2.37% at $0.9226 with 1.36 million shares, compared to its average volume of 1.40 million shares. The stock moved within a range of $0.9020 – 0.9385 after opening trade at $0.9315.
In light of this situation, it may be a good idea for investors to consider taking a closer look at Northwest and then make up their minds about the stock one way or another. At this point in time, the release of the top line data from the Phase 3 trial of the company’s product DCVax-L is expected to be a significant trigger for the stock.
Investors are waiting with great anticipation for the data and there is a degree of speculation among many that the company could be on the cusp of something major. The product in question is meant for treating or curing the most deadly forms of cancer and hence, the excitement about it is understandable.
At this point in time, investors could consider adding the Northwest stock to their watch lists and consider keeping an eye on the developments as and when they occur. It remains to be seen if the stock can actually add to its gains in the coming days.
NWBO stock is trading above the 20-Day and 50-Day Moving averages of $0.87 and $0.83 respectively. Moreover, the stock is trading below the 200-Day moving average of $1.